CStone Pharmaceuticals (“CStone”) today announced the recent approval of investigational new drug (IND) application from the United States Food and Drug Administration (FDA) for CS1001, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
